Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies

(Worcester Polytechnic Institute) A novel robot that can operate inside the bore of an MRI scanner is currently being tested as part of a biomedical research partnership program at Brigham and Women's Hospital in Boston with the aim of determining if the robot, in conjunction with real-time MRI images, can make prostate cancer biopsies faster, more accurate, less costly, and less discomforting. The system also has the potential to deliver prostate cancer therapies with greater precision.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news

Related Links:

PHILADELPHIA - With the addition of F-18 fluciclovine to PET/CT scans, clinicians...Read more on AuntMinnie.comRelated Reading: SNMMI: Early prostate cancer therapy extends lives SNMMI: Molecular imaging method monitors gene therapy Blue Earth promotes results for PET/CT agent Blue Earth touts addition of Axumin to NCCN guidelines Novel PET tracer aids recurrent prostate cancer patients
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
535Objectives: Targeted radionuclide therapy (TRT) has recently gained great momentum due to the promising results achieved in the treatment of neuroendocrine and prostate cancer. However, similar approaches elude breast cancer therapies given the lack of radiopharmaceuticals that effectively target breast cancer. Our goal is to develop a theranostic strategy that uses a novel alkylphosphocholine analog (NM600) labeled with 86Y for targeted PET imaging and 177Lu for TRT in a syngeneic murine model of breast cancer. Methods: NM600 was synthesized by conjugating 18-(p-aminophenyl)octadecyl phosphocholine to the chelator DOTA...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Preclinical Probes for Oncology II Source Type: research
Abstract There are over a dozen of approved cancer drugs, whose administration is tailored to predictive laboratory tests. The examples include estrogen and progesterone receptor status determination for the use of endocrine therapy, HER2 assessment for the administration of HER2-targeting agents, EGFR and ALK gene testing for lung cancer treatment, BRAF analysis in melanoma, etc. While first predictive tests relied on relatively easy laboratory procedures, more recent developments require rather sophisticated assays. For example, administration of PARP inhibitors is tailored to a comprehensive testing of BRCA1 an...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
This study aimed to investigate the effects of plumbagin-loaded prostate-specific membrane antigen (PSMA) aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol (PLGA-PEG) nanoparticles (NPs) on prostate cancer (PCa) in vitro. PLGA–PEG with a terminal carboxylic acid group (PLGA-PEG-COOH) was synthesized, and plumbagin was loaded on PLGA-PEG-COOH NPs using the nanoprecipitation method and characterized by field emission scanning electron microscopy (SEM), transmission electron microscopy (TEM), and laser light scattering. The uptake and distribution of plumbagin-NPs in human PCa LNCaP cells were inv...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Conclusion: The use of 177 Lu-PSMA therapy demonstrates lowered PSA and pain levels in metastatic castration resistant prostate cancer patient’s who have not responded or no longer responds to chemotherapy or hormone treatments. The positive outcome sustained with the use of 177-Lu used in cancer therapy is credited to the radiopharmaceutical’s longer half-life of 6.7 days combined with PSMA naturally encoded in the human gene. With the development of 177 Lu-PSMA, studies have shown promising results of overall improvement in quality of life for metastatic castration resistant prostate cancer patients. The pote...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Technologist Student Papers I Source Type: research
Molecular imaging using radiopharmaceuticals has a clear role in visualising the presence and extent of tumour at diagnosis and monitoring response to therapy. Such imaging provides prognostic and predictive information relevant to management, e.g. by quantifying active tumour mass using positron emission tomography/computed tomography (PET/CT). As these techniques require only pharmacologically inactive doses, age and potential frailty are generally not important. However, this may be different for therapy involving radionuclides because the radiation can impact normal bodily function (e.g.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Position Paper Source Type: research
The technology 'fuses' an MRI (magnetic resonance imaging) scanner with ultrasound to identify diseased cells. A precisely targeted laser fibre is then heated up to annihilate them.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
1161Objectives  Targeted therapy has become an effective strategy of precision medicine for better treatments of cancer. Based on the encouraging results from the therapies of lymphoma and breast cancer by antibody-drug conjugates (ADCs), here we describe a theranostic small-molecule drug conjugate (T-SMDC) design for prostate cancer therapy by targeting prostate specific membrane antigen (PSMA) for drug delivery and incorporating a positron emission tomography (PET) imaging component enabled by 68Ga (β+, t1/2 = 68 min) for concurrent noninvasive PET evaluation of the therapy.Methods  The design of T-SMDC, N...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: SPECIAL MTA: Preclinical Probes for Oncology Posters Source Type: research
Conclusions We designed and synthesized two SCD-1 targeting radiotracers, 18F-FPPPT and 18F-FAPPT, and showed the ability of PET with 18F-FPPPT to quantify the SCD-1 expression level in tumors. Research Support: This study was partially supported by a grant from the National Institutes of Health (R01DK092163) and the Dr. Jack Krohmer Professorship Funds.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: SPECIAL MTA: Preclinical Probes for Oncology Posters Source Type: research
Abstract Background and purpose Intensity-modulated particle therapy (IMPT) for tumors showing interfraction motion is a topic of current research. The purpose of this work is to compare three treatment strategies for IMPT to determine potential advantages and disadvantages of ion prostate cancer therapy. Materials and methods Simulations for three treatment strategies, conventional one-plan radiotherapy (ConvRT), image-guided radiotherapy (IGRT), and online adaptive radiotherapy (ART) were performed employing a dataset of 10 prostate cancer patient...
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hospitals | International Medicine & Public Health | Partnerships | PET Scan | Prostate Cancer | Women